Status:
RECRUITING
Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
Harvard Pilgrim Health Care Institute
Centers for Disease Control and Prevention
Conditions:
C. Difficile
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clostridioides difficile (C. difficile) is the most common healthcare-associated pathogen, causing \>500,000 infections and \>29,000 deaths per year in the US. Traditional approaches to reduce hospita...
Eligibility Criteria
Inclusion
- Patients admitted to ICU or Oncology units and identified to carry C. Difficile via VRE swab
Exclusion
- Patients not identified as carriers of C. difficile and patients not admitted to ICU or oncology units
Key Trial Info
Start Date :
July 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05389904
Start Date
July 25 2022
End Date
August 1 2026
Last Update
August 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115